Tag: GlobeNewswire

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — Xali Gold Corp. (TSXV:XGC) (“Xali Gold” or the “Company”) is pleased to announce that a public information workshop was successfully completed on October 7, 2026, as part of the Ficha Técnica Ambiental (“FTA”) approval process for the planned drilling program at its Pico Machay Gold Project (“Pico Machay” or the “Project”) in Peru. Completion of the workshop marks an important step toward submission of the Company’s FTA application.

The workshop was organized by Peru’s Ministry of Energy and Mines (“MINEM”), in coordination with the executives of the department of Energy and Mines of the Regional Government of Huancavelica and the Company. Approximately 60 residents attended from the various annexes of the Comunidad Campesina de Salcca Santa Ana (“Santa Ana community”) within the Project’s area of influence, including the presidents of five of its six annexes, the community president and two members of the community’s governing board, and the president of the alpaca breeders’ association.

Participants had the opportunity to hear directly from and ask questions of government representatives, Geades Consultores, the Company’s Peru-based environmental consultant, and Xali Gold’s team. Discussions covered the proposed drilling program, environmental and social aspects of exploration, applicable laws and measures to protect community interests, as well as the Company’s broader exploration and potential development plans.

“Completion of this workshop is an important step in advancing our exploration permit application and continuing an open dialogue with the Santa Ana community,” said Joanne Freeze, President and CEO of Xali Gold. “The participation and questions raised demonstrate the community’s interest in understanding the proposed work, how the environment will be protected and the laws that govern our activities. We thank all community members who attended, MINEM, the Regional Government of Huancavelica, Geades Consultores and our team for their contributions.”

Image 1: Public information workshop with members of the Santa Ana community, government representatives, environmental consultants and Xali Gold’s team on October 7, 2026.

FTA Process and Next Steps

As reported in Xali Gold’s September 17, 2026 news release, the Company completed two technical meetings with Peru’s MINEM to obtain guidance on updated FTA requirements. Xali Gold also engaged Embellie Advisory LLC to assess potential effects of the proposed drilling on the collective rights of indigenous or native community members and assist with the related application requirements.

With the workshop now completed, the Company is working to finalize its FTA application, with submission targeted for next week. Based on guidance received, the review and approval process is anticipated to take approximately 10 days following submission, although actual timing remains subject to the regulatory process.

The planned 3,000-metre diamond drill program includes approximately 2,000 metres of drilling to twin selected historical reverse-circulation holes. This work is intended to support an updated mineral resource estimate and subsequent Preliminary Economic Assessment.

Ongoing Community Engagement

The workshop builds on the community authorization announced in Xali Gold’s July 9, 2026 news release. At an extraordinary assembly held on June 28, 2026, the Santa Ana community authorized the Company to undertake drilling, exploration and environmental studies at Pico Machay.

Xali Gold remains committed to ongoing engagement with the community as the Project advances, with an emphasis on transparent communication, respect for local priorities and opportunities for community participation.

About Pico Machay

Located within the Southern Peru Epithermal Gold-Silver Belt, Pico Machay sits in a historically productive mining district in the Western Cordillera of the Andes (click here for location map). The Project benefits from existing infrastructure and a mining-friendly community eager to partner on sustainable development.

Xali Gold remains confident in the significant upside potential at Pico Machay, which hosts a historical resource and several untested exploration targets on the Project. Various historical engineering studies at Pico Machay were completed through 2009 and evaluated the potential for a low-cost, low strip-ratio, open-pit heap-leach operation. Given that those studies were based on a long-term gold price of $700/oz and several exploration targets remain untested, Xali Gold considers the upside potential to be very strong.

About Xali Gold

Xali Gold is a gold and silver exploration company focused on advancing opportunities in the Americas. The Company is focused on the exploration and development of Pico Machay, an advanced exploration-stage gold project in Peru with a near-term production goal. 

The Company’s approach to community engagement and responsible development is guided by strong governance principles and Board oversight that support long-term stakeholder relationships.

Joanne C. Freeze, P.Geo. is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the contents of this release.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

On behalf of the Board of Xali Gold Corp.

“Joanne Freeze” P.Geo.
President, CEO and Director

For further information please contact:
Joanne Freeze, President & CEO                                
Tel: + 1 (604) 512-3359                                                                 
info@xaligold.com                

Forward-looking Disclaimer
This press release contains forward-looking information within the meaning of Canadian securities laws (“forward-looking statements”). Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, plans, postulate and similar expressions, or are those, which, by their nature, refer to future events. All statements that are not statements of historical fact are forward-looking statements.

Forward-looking statements in this press release include, without limitation, statements regarding: the finalization and submission of the FTA application, including the anticipated submission approximately one week after the public workshop; the anticipated review and approval period of approximately 10 days following submission and receipt of approval, if at all; the completion of final preparations for drilling; the commencement, scope, timing and completion of the planned 3,000-metre diamond drill program, including approximately 2,000 metres of drilling to twin selected historical reverse-circulation holes; the anticipated contribution of the drilling program to an updated mineral resource estimate and subsequent Preliminary Economic Assessment; ongoing community engagement and opportunities for community participation; and the continued exploration, advancement and potential development of the Project.

These forward-looking statements are made as of the date of this press release. Although the Company believes the forward-looking statements in this press release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.

Known risk factors and assumptions include risks associated with exploration and project development; accessing further funding and related dilution: continuing its projected growth, or being fully able to implement its business strategies; the calculation of mineral resources and additional work required to convert historical resources to current mineral resources; the nature, quality and quantity of any mineral deposits that may be located on the project; operational risks associated with mining and mineral processing; fluctuations in metal prices and assumptions including costs; title matters; government regulation; obtaining and renewing necessary consents, authorizations, licenses and permits; environmental liability and insurance; reliance on key personnel; local community opposition; currency fluctuations; labour disputes; competition; variations in market conditions, and the volatility of our common share price and volume; future sales of shares by existing shareholders; and other risk factors described in Xali Gold’s MD&A and other filings with Canadian securities regulators, which may be viewed at www.sedarplus.ca. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Xali Gold expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b16bc583-d325-4aa2-ab94-f0e9810064dc

New Intelligence Layer Helps Contractors Identify Operational Challenges, Make Smarter Decisions, and Drive Profitable Growth

ORLANDO, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) — Aspire Software, a ServiceTitan company and leading software provider for landscape businesses, today announced that it will unveil Command Center at Ignite 2026, Aspire’s annual user conference, with limited access opening to a limited group of Aspire customers. A new intelligence layer across Aspire, Command Center gives landscape contractors a near real-time view of their operations, helping them identify issues and opportunities sooner, make more informed decisions, improve efficiency, and drive profitable growth.

“Landscape contractors have an incredible amount of data across their businesses, but the real value comes from being able to understand what that data is telling them and use it to make better decisions,” said Vahe Kuzoyan, Co-Founder and President of ServiceTitan. “Command Center is designed to bring intelligence to the forefront, helping contractors understand what’s happening across their operations, identify opportunities sooner, and focus their attention where it can have the greatest impact on their business.”

Rather than relying on static reports, overnight data synchronization, or third-party analytics tools, contractors can access near real-time insights across individual branches or their entire business, helping them identify issues and opportunities and make more informed decisions.

By bringing together Aspire’s foundational business data with Atlas, ServiceTitan’s conversational agent, Command Center is purpose-built for the way landscape businesses operate. Contractors can ask questions about their business, create customized dashboards, and proactively identify opportunities to improve performance, with an experience that becomes more tailored to the needs of their business over time.

Command Center will introduce new AI-powered capabilities designed to:

• Turn business data into actionable insights: Give contractors a near real-time view of operational and financial performance across their business, helping them identify issues and opportunities and determine where action may be needed.
• Simplify business intelligence with conversational AI: Enable users to ask Atlas questions about their business data in plain English and generate customized charts and dashboards without specialized technical expertise.
• Proactively identify operational challenges: Surface issues such as declining crew productivity, overdue invoices, and eroding contract margins through automated alerts delivered via email.
• Build customized alerts and dashboards: Allow users to describe the information they want to monitor in plain English, create alerts tailored to their business, and access ready-made dashboards without relying on dedicated analysts or complex reporting tools.

Command Center early access will be limited to 100 Aspire customers, with general availability expected early next year. For more information about Aspire Software, Command Center, and Ignite, follow Ignite’s Live Blog here.

About Aspire Software
Aspire Software, a ServiceTitan company, offers business management software for landscape maintenance, landscape construction, and snow & ice management companies. Aspire’s cloud-based SaaS solution helps field service companies manage, create, and execute against their business opportunities and challenges. Aspire helps contractors change the way they manage their business to enable them to provide better service, improve margins, and increase productivity. For more information, please visit http://www.youraspire.com.

© 2026 Aspire Software. All rights reserved. Aspire Software, the Aspire Software logo, and all Aspire Software product and service names mentioned herein are registered trademarks or unregistered trademarks of Aspire Software in the United States and other countries. Other brand names and marks mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s).

Press Contact
Sarah Cantu
press@youraspire.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release may be forward-looking statements. These include statements regarding the plans of Aspire Software and its parent company, ServiceTitan, Inc. (“ServiceTitan”), for current or future products, services or features, including Command Center, Atlas, and other AI-powered and agentic functionality or features; the expected availability, timing, capabilities and benefits of those products, services and features, including their ability to deliver near real-time insights, surface operational issues, and become more tailored to a business over time; and Aspire and ServiceTitan’s market positioning and business strategy. They also include statements identified by words such as “expects,” “anticipates,” “believes,” “plans,” “intends,” “will,” “designed to,” and similar expressions. These forward-looking statements are not promises or guarantees of future results. They are based on current expectations only and are subject to various risks and uncertainties, including those described in ServiceTitan’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as updated in its other filings with the U.S. Securities and Exchange Commission from time to time. Actual results may differ materially from those anticipated in these statements due to several factors, including those referenced in ServiceTitan’s filings with the U.S. Securities and Exchange Commission. Products, services or features described in this press release that are not currently generally available may not be delivered on the anticipated timeline or at all. Purchasing decisions should be based on products, services and features that are currently generally available. Forward-looking statements, including those made during the Ignite 2026 keynote sessions and any replay of them, speak only as of the date they are made, and neither Aspire nor ServiceTitan undertakes any obligation to update any forward-looking statements, except as required by law.

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that the first patient has been dosed in its pivotal Phase 2 study of CLN-049, a novel, investigational FLT3 T cell engager, in patients with relapsed/refractory acute myeloid leukemia (AML).

“Patients with relapsed or refractory AML continue to face poor outcomes and limited treatment options, underscoring the urgent need for new treatment approaches that can benefit a broad range of patients,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “We believe CLN-049 has the potential to offer a novel immunotherapeutic approach for patients with AML. With this Phase 2 study now underway, we look forward to further evaluating the potential role of CLN-049 for this difficult-to-treat disease.”

The Phase 2 study is designed to evaluate CLN-049 in patients with relapsed/refractory AML who have received up to two lines of prior therapy. Following a successful End-of-Phase 1 meeting with the U.S. FDA, the potentially registrational study incorporates a brief dose-optimization phase evaluating two target dose levels of CLN-049, followed by seamless advancement to a single-arm expansion cohort at the recommended Phase 2 dose. The study also includes an exploratory cohort evaluating CLN-049 in patients with newly diagnosed TP53-mutated AML. The company expects to provide an update from the Phase 1 dose escalation study of CLN-049 in patients with relapsed/refractory AML in December.

In parallel, the company is initiating a Phase 1/2 study evaluating the combination of CLN-049, azacitidine, and venetoclax in patients with newly diagnosed AML.

About CLN-049

CLN-049 is a novel, investigational FLT3xCD3 T cell engager. CLN-049 is designed to target FLT3-expressing leukemia cells, offering a new immunotherapeutic approach for treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CLN-049 binds to both mutated and non-mutated FLT3, allowing targeted action regardless of FLT3 mutational status, making the investigational treatment widely applicable to a broad population.

CLN-049 is being studied in a Phase 1/2, open-label, multicenter, multiple ascending dose study evaluating safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of intravenously (IV) administered CLN-049 in patients with relapsed/refractory AML or MDS (NCT05143996).

CLN-049 is also being studied in a Phase 1/2, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and PD of IV-administered CLN-049 in combination with azacitidine and venetoclax in patients with newly diagnosed AML (NCT07722767).

CLN-049 has received Orphan Drug designation and Fast Track designation from the U.S. FDA for the treatment of relapsed/refractory AML.

About Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow, and the most common form of acute leukemia in adults.¹ It is characterized by the rapid growth of abnormal white blood cells that crowd out healthy cells, leading to infections, fatigue, and bleeding.² Each year in the U.S., approximately 23,000 people are diagnosed with AML, and about half as many lives are lost to the disease.³ Globally, AML affects an estimated 145,000 people annually, with approximately 130,000 deaths.⁴

Despite recent advances, outcomes for patients with AML remain poor, particularly for those with relapsed or refractory disease, where five-year survival is 10% or less.⁵ Patients with high-risk genetic features, such as complex karyotype or TP53 mutations, face especially limited options.^6,7 Intensive treatments like chemotherapy and stem cell transplantation may be inaccessible for many older patients due to severe side effects.⁷ Currently, there are no approved immunotherapies for AML, underscoring the urgent need for novel therapeutic approaches that can improve outcomes for patients and their families facing this life-threatening disease.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: our clinical development plans and timelines for CLN-049, the clinical and therapeutic potential of CLN-049, the strategy of CLN-049, our research and development activities, and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any INDs, NDAs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared or approved on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Contacts

Investors
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com

Media 
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com

References

1. American Association for Cancer Research. (2025). Acute Myeloid Leukemia. https://www.aacr.org/patients-caregivers/cancer/acute-myeloid-leukemia/
2. Leptidis, J., et al. (2014). Fatal cardiac tamponade as the first manifestation of acute myeloid leukemia. Am J Emerg Med 32(10). https://doi.org/10.1016/j.ajem.2014.02.045
3. National Cancer Institute. (2025). Cancer Stat Facts: Leukemia — Acute Myeloid Leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html
4. Zhou, Y., et al. (2024). Global, regional, and national burden of acute myeloid leukemia, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Biomarker Research, 12(101). https://doi.org/10.1186/s40364-024-00649-y
5. Moore, CG., et al. (2025). Treatment of Relapsed/Refractory AML—Novel Treatment Options Including Immunotherapy. Am J Hematol. (100)2. https://doi.org/10.1002/ajh.27584
6. Shahzad, M., et al. (2024). What have we learned about TP53-mutated acute myeloid leukemia?. Blood Cancer J. 14(202). https://doi.org/10.1038/s41408-024-01186-5
7. Kantarjian, H., et al. (2021). Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 11(2). https://doi.org/10.1038/s41408-021-00425-3 

SAGUENAY, Quebec, Oct. 08, 2026 (GLOBE NEWSWIRE) — Arianne Phosphate (the “Company” or “Arianne”) (TSX VENTURE: DAN; OTCQB: DRRSF; FRANKFURT: JE9N), a development-stage phosphate mining company, advancing the Lac à Paul project in Quebec’s Saguenay-Lac-Saint-Jean region, is pleased to announce the receipt of positive test results from a Western-based battery materials maker, advancing its goal of a fully integrated North American battery supply chain. The purified phosphoric acid (“PPA”) tested was produced through Arianne’s previously announced joint venture with Travertine Technologies Inc. (“Travertine”), combining Arianne’s high-purity, low-contaminant phosphate concentrate with Travertine’s proprietary process for producing PPA while allowing for the recapture of the sulphuric acid used in the process.

As previously announced (see Press Release dated July 9, 2026), Arianne shipped PPA samples to potential customers covering three separate industries: a CAM producer for ultimate use in LFP (lithium-iron-phosphate) batteries, a diversified industrial chemicals producer that uses PPA for water treatment and pulp & paper applications and a specialized liquid fertilizer producer. The samples were produced at pilot scale by the Arianne-Travertine partnership. The CAM producer referenced in that release has now completed preliminary testing and confirmed that the PPA meets the indicative specifications required for its LFP CAM production.

“Having our PPA meet the specifications of a CAM producer is a significant milestone for Arianne and our Travertine JV project,” said Brian Ostroff, Head of Strategic & Business Initiatives at Arianne Phosphate. “The LFP battery has some of the most demanding purity requirements of any application for phosphoric acid and these results validate what we have been saying for some time: our high-purity, low-contaminant phosphate concentrate allows for the production of a PPA suited for the most demanding applications. With LFP demand growing rapidly and the West looking to reduce its reliance on a single source of supply, being able to offer a Western-sourced PPA is something we believe will be of considerable interest.”

Aside from its use in the LFP battery, PPA is a necessary ingredient for many applications required in everyday use. Food additives, pharmaceuticals, semiconductor production and water treatment are all reliant on access to this critical liquid and Western production currently does not meet industry’s requirement. Further complicating supply challenges are the current disruptions to the global supply of sulphur, a necessary component in the processing of many commodities, including phosphate concentrate into all downstream products.

Arianne Phosphate’s Lac à Paul project is situated in Quebec, Canada and hosts the world’s largest greenfield phosphate deposit. Being igneous, the ore body is geologically rare and allows for the easy transformation into a high-quality, premium-priced PPA. As the West’s only permitted greenfield phosphate mine, Arianne can address the growing demand for this critical material and do so from geopolitically secure jurisdiction. The Company’s JV project with Travertine will also greatly reduce (95%) the requirements of sulphuric acid and potentially significantly reduce OpEx costs associated with PPA production.

In April, Arianne announced that it had entered into an option agreement on behalf of the future Arianne/Travertine JV for a facility to be used as a demonstration plant for the production of PPA using this proprietary process (see Press Release dated April 21, 2026). The facility is based in the Saguenay-Lac-Saint-Jean region of Quebec, Canada; easy trucking distance from Arianne’s future mine site. Advancing this project has the potential to form a Canadian supply chain for LFP battery materials, from phosphate mine to production of acid, and ultimately to the cathode. Like most battery technologies, China currently dominates LFP production and, as the West continues to adopt the LFP for electric vehicles, energy storage and defense applications, production from other geographies will be necessary.

About Arianne Phosphate:
Arianne Phosphate (“Arianne Phosphate Inc.”) (www.arianne-inc.com) is developing the Lac à Paul phosphate deposits located approximately 200 km north of the Saguenay/Lac St. Jean area of Quebec, Canada. These deposits will produce a high-quality igneous apatite concentrate grading 39% P₂O₅ with little or no contaminants (Feasibility Study released in 2013).

About Travertine: 
Travertine was founded in 2022 to solve one or the most pressing problems in the mining industry: producing vital elements without creating mountains of waste. Their proprietary electrochemical technology completely converts phosphate ore concentrate into valuable products – phosphoric acid, cementitious materials, and co-produced critical elements – closing the loop between the extraction and construction industries for cleaner chemical production. Their gypsum-free, solvent-free process will become the standard for next generation, cleaner purified phosphoric acid production. To learn more, visit www.travertinetech.com. 

Qualified Person
Raphael Gaudreault, eng., Qualified Person by Regulation 43-101, has approved the technical information in this release. Mr. Gaudreault is also the Company’s Chief Operating Officer.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Technical	Info
Raphael Gaudreault	Brian Ostroff
Chief Operating Officer	Head of Strategic & Business Initiatives
Tel.: 418-590-1318	Tel.: 514-928-9952
raphael.gaudreault@arianne-inc.com	brian.ostroff@arianne-inc.com

Follow Arianne on:
Facebook: https://www.facebook.com/ariannephosphate
Twitter: http://twitter.com/arianne_dan
YouTube: http://www.youtube.com/user/ArianneResources
Flickr: http://www.flickr.com/photos/arianneresources
Resource Investing News: http://resourceinvestingnews.com/?s=Arianne

Cautionary Statements Regarding Forward Looking Information

This news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities regulations in Canada and the United States (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, the Company’s anticipated quality and production of the apatite concentrate at the Lac à Paul project. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects, “is expected”, “budget”, “scheduled”, “estimates”, forecasts”, “intends”, “anticipates”, or “believes”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, or “will” be taken, occur or be achieved.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: unforeseen delays in the execution of the definitive agreements in connection with the credit facility extension or in obtaining regulatory approval; inability to complete the credit facilities extension by the Closing Date; volatile stock price; risks related to changes in commodity prices; sources and cost of power facilities; the estimation of initial and sustaining capital requirements; the estimation of labour and operating costs; the general global markets and economic conditions; the risk associated with exploration, development and operations of mineral deposits; the estimation of mineral reserves and resources; the risks associated with uninsurable risks arising during the course of exploration, development and production; risks associated with currency fluctuations; environmental risks; competition faced in securing experienced personnel; access to adequate infrastructure to support mining, processing, development and exploration activities; the risks associated with changes in the mining regulatory regime governing the Company; completion of the environmental assessment process; risks related to regulatory and permitting delays; risks related to potential conflicts of interest; the reliance on key personnel; financing, capitalization and liquidity risks including the risk that the financing necessary to fund continued exploration and development activities at Lac à Paul project may not be available on satisfactory terms, or at all; the risk of potential dilution through the issue of common shares; the risk of litigation.

Forward-looking information is based on assumptions management believes to be reasonable at the time such statements are made, including but not limited to, the material terms of the credit facility extension having been agreed to by the parties, continued exploration activities, no material adverse change in commodity prices, exploration and development plans proceeding in accordance with plans and such plans achieving their stated expected outcomes, receipt of required regulatory approval, and such other assumptions and factors as set out herein. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is made as of the date of this press release, and the Company does not undertake to update such forward-looking information except in accordance with applicable securities laws.

– Repayment of Existing Loan Facility Completed –

– Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities –

– Expect Completion of Enrollment in Phase 3 4WARD trial by Year-End 2026 and Topline Data in H1 2028 –

BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that it has entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures LLC (“K2HV”), an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries. The K2HV facility replaces a prior loan agreement and strengthens X4’s financial flexibility.

The first tranche of $80 million funded at closing and was used to repay in full all obligations, including $75 million of principal and related fees, under the Company’s prior loan and security agreement, along with associated closing costs. An additional $70 million may be made available to X4 at the Company’s request, subject to approval by K2HV and other conditions. The new K2HV facility provides a larger total facility size, a longer interest-only period, and a 48-month maturity to support corporate activities, including the potential future commercial launch of mavorixafor in chronic neutropenia.

“Our partnership with K2 HealthVentures strengthens our capital position and gives us a solid financial foundation as we advance mavorixafor toward potential FDA approval and a commercial launch in chronic neutropenia,” said David Kirske, Chief Financial Officer of X4. “The new structure provides additional flexibility on more favorable terms and is aligned with our strategic priorities. We expect to reach several key milestones in the near term, including completing enrollment in our Phase 3 4WARD trial this year and reporting topline results in the first half of 2028. We are executing with focus, discipline, and a clear line of sight to what matters most.”

“We are pleased to partner with X4 Pharmaceuticals as it advances mavorixafor for the potential treatment of people living with rare hematology diseases. This financing reflects our strategy of serving as a long-term financing partner to innovative life sciences companies, and we look forward to supporting X4’s next phase of growth,” said Parag Shah, Founding Managing Director and Chief Executive Officer of K2 HealthVentures.

Additional details regarding the loan agreement will be included in filings with the U.S. Securities and Exchange Commission (SEC). For more information, please visit the Company’s Investor website, which includes SEC filings and other data sources.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI^® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Forward Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4’s expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding the anticipated use of proceeds from the K2HV loan facility, the availability of additional tranches under the facility, the potential extension of the interest-only period, the sufficiency of the Company’s cash resources and its expected cash runway, the potential addressable market for moderate and severe chronic neutropenia, the expected timing for completion of enrollment in, and topline data from, the 4WARD trial, the timing for launch of mavorixafor in chronic neutropenia and future plans for the Company. Any forward-looking statements in this press release are based on management’s current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: X4 may not satisfy the conditions required to access additional tranches under the K2HV facility or obtain K2HV’s approval of such draws; X4 may be unable to comply with the covenants under the loan agreement, including minimum cash and minimum revenue covenants; the interest-only period may not be extended if first commercial U.S. sales of mavorixafor in chronic neutropenia are not achieved on the anticipated timeline; changes in the prime rate may increase X4’s interest expense; enrollment in the 4WARD trial may not be completed, and topline data may not be reported, within the expected timeframes, or at all; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s most recent Annual Report on X4’s Form 10-K, as well as in other filings X4 makes with the Securities and Exchange Commission, including its quarterly reports on Form 10-Q, from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
IR@X4pharma.com

Source: X4 Pharmaceuticals, Inc.

Maximizes Customer Value With More Kilowatt Hours Per Year

OREM, Utah, Oct. 08, 2026 (GLOBE NEWSWIRE) — SunPower Inc. (“SunPower,” or Nasdaq: “SPWR”) a solar technology, services, and installation company, today announced a new Monolith platform product, the Monolith II next-generation premium high-wattage panel, designed as part of its Joint Development Agreement (JDA) with REC and exclusive to SunPower. Monolith II set the latest SunPower panel power record since its 333-watt record in 2009. Monolith II maximizes total kilowatt hours (KWh) per year, literally the actual “payback” of solar systems.

SunPower successfully commercialized Monolith, a 470-watt panel developed by the SunPower-REC JDA. The Monolith panel uses REC’s advanced N-Type Heterojunction (HJT) cell technology, which provides superior power output and annual energy production, exceptional aesthetics and a solid 25-year warrantee. Monolith II panels produce 522 watts from the first Monolith footprint and weight by encapsulating REC’s N-Type HJT wafer technology in a “bifacial” panel with glass on both the front and back sides to illuminate the cells from both sides.

Starbucks: SunPower used commercial size bifacial panels on 67 Starbuck’s stores to maximize the annual energy (kWh) and economic output from a given store footprint. The panels receive full sunlight on the top and reflected sunlight on the bottom

T.J. Rodgers, SunPower CEO, said, “Our partners at REC have done it again, enabling us to offer our new customers the market’s most powerful residential panel, as well as offering our 415,000 legacy customers an attractive system upgrade. Monolith II weighs less than 50 pounds, as mandated by OSHA for single-worker installation, yet produces 522 watts. To illustrate customer value, my backyard vineyard has three rows replaced with 56 SunPower 360-watt panels that produce 20,160 watts. With Monolith II, the system will produce 29,323 watts, or 46 kWh of extra energy per day, worth $3,345 per year in California.”

Brian Ghiglia, REC Americas VP of Sales, said, “We are excited to continue our R&D collaboration with SunPower which provides us with early engineering data so we can rapidly improve our solar technology.”

Surinder S. Bedi, SunPower’s Executive Vice President of Quality, Engineering and Customer Success, concluded, “With five years of personal experience building bifacial commercial systems, I cannot wait to get our first Monolith II installation done this month on the roof of a Cobalt Silicon Valley customer who will allow us to compare Monolith vs Monolith II side by side.”

About SunPower
SunPower (Nasdaq: SPWR) is a solar technology, services, and installation company focused on delivering reliable and affordable energy solutions. Through its national operating platform and specialized subsidiaries, SunPower serves residential, commercial, new-home, and multifamily customers across the United States. For more information visit www.sunpower.com.

About REC Solar:
Founded in 1996, REC Group is an international pioneering solar energy company dedicated to empowering consumers with clean, affordable solar power. As Solar’s Most Trusted, REC is committed to high quality, innovation, and a low carbon footprint in the solar materials and solar panels it manufactures. Headquartered in Norway with operational headquarters in Singapore, REC also has regional hubs in North America, Europe, and Asia-Pacific. For more information visit www.recgroup.com.

Forward Looking Statements
This press release contains forward-looking statements, including statements concerning the equity for interest exchange and related impacts of the transactions. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “seek,” “plan,” “project,” “target,” “looking ahead,” “look to,” “move into,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements represent SunPower’s current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing SunPower’s estimates as of any subsequent date. Forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Risks include, but are not limited to market risks, trends and conditions. These risks are not exhaustive. For additional information on these risks and uncertainties and other potential factors that could cause actual results to differ from the results predicted, readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our annual report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 14, 2026, our quarterly reports on Form 10-Q filed with the SEC, and other documents that we have filed with, or will file with, the SEC. Such filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SunPower assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contact:

Sioban Hickie
VP Investor Relations
IR@sunpower.com
(801) 515-8727

Source: SunPower Inc.

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/7a1d04fa-4b91-4e2b-8ed3-a5f66b8f03a1
https://www.globenewswire.com/NewsRoom/AttachmentNg/2a90f2a1-a8f7-499f-9b81-69b2f0ad0cb0

Nutriband files new non-provisional patent application to strengthen intellectual property protection of its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.

Nutriband’s AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure.

ORLANDO, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB) today announced that it has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office (USPTO) to further strengthen Nutriband’s intellectual property protection for its AVERSA™ abuse deterrent transdermal technology.

This new patent application covers improved aversive formulations and coating application methods to enhance the abuse deterrent properties of Nutriband’s AVERSA™ transdermal technology and make it even more difficult to defeat. If this new patent is subsequently granted, it could significantly extend the patent protection for products that utilize Nutriband’s AVERSA™ abuse deterrent technology as the statutory patent term of a US patent is 20 years from the non-provisional filing date. If granted, the worldwide (PCT) patent protection for AVERSA™-based products such as AVERSA™ FENTANYL could be extended to 2046.

The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

Nutriband’s AVERSA™ abuse-deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as opioids, while making sure that these drugs remain accessible to those patients who really need them.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12^th to 14^th at The Hard Rock Hotel New York, in New York City.

Gain Therapeutics will be meeting with institutional investors in one-on-one meeting sessions and engaging with senior Maxim research analysts throughout the event.

If you are interested in meeting with Gain management, please contact your Maxim sales representative to schedule.

About the Maxim Growth Summit

This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

Keynote speakers include Marcus Lemonis (co-owner of Camping World and executive chairman of Neighborhood Intelligence) and Eric Adams (former mayor of New York City). The conference will also feature roundtable discussions with CEOs from small- and mid-cap companies, moderated by Maxim research analysts. Roundtable discussions will cover a range of sectors, including biotechnology, artificial intelligence, quantum technology, digital assets, energy and mining, drones, and more.

This year, portions of the event will also be streamed online at https://digital.maximgrp.com/.

For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2026-growth-summit.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next-generation allosteric therapies. Gain’s lead drug candidate, rexaceract is currently being evaluated for the treatment of PD with or without a GBA1 mutation in a Phase 1b clinical trial. Rexaceract has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates; expectations regarding the timing of patient enrollment and the completion and timing of results from a Phase 1b clinical study for rexaceract, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies; the timing of the commencement of the Phase 2 clinical study for rexaceract; the Company’s ability to enroll patients in its planned Phase 2 clinical study for rexaceract; the Company’s ability to replicate positive results from earlier preclinical studies or clinical trials in current or future clinical trials; the Company’s business development activities, strategic collaborations, licensing opportunities and financing activities; the advancement, prioritization and timing of the Company’s pipeline programs, including GT-04686; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2025, and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.

Investors:
Gain Therapeutics, Inc. 
Apaar Jammu 
Director, Investor Relations and Public Relations
ajammu@gaintherapeutics.com

LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com

Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256

First-Quarter Results Reinforce Tilray’s Progress Converting Global Scale, Disciplined Execution and Category Leadership into Higher Revenue, Expanded Gross Profit and Continued Momentum

Record First-Quarter Net Revenue of $257 Million, Up 23% Year-Over-Year, with Gross Margin Expanding by ~300 bps to 30%

International Business Accelerates as EMEA Revenue Increases 71%, Growth Led by Medical Cannabis, Beverage and Pharmaceutical Distribution

Tilray’s Global Beverage Business Delivers $101 Million in Revenue, Expands Gross Margin to 41% and BrewDog Achieves Profitability in Q1

Reduced Outstanding Debt by $42 Million Fiscal Year-to-Date and Ended the Q1 with a Net Cash¹ Position, Strengthening Financial Flexibility and the Balance Sheet

Tilray Reaffirms Fiscal 2027 Adjusted EBITDA³ Guidance of $68 Million to $75 Million

NEW YORK and LONDON and LEAMINGTON, Ontario, Oct. 08, 2026 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company with leading positions across cannabis, beverage, hospitality and wellness, today reported financial results for its first fiscal quarter ended August 31, 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, stated: “Tilray’s record first-quarter revenue and gross profit demonstrate the power of the diversified platform we have built and the momentum we are creating across cannabis, beverage, hospitality, wellness and pharmaceutical distribution. We are no longer dependent on a single market or regulatory catalyst. We have multiple engines of growth, a scaled international footprint and the ability to convert scale into stronger margins, greater efficiency and sustainable, profitable growth.”

Mr. Simon continued, “Our global platform is translating into leadership positions across our core categories. In cannabis, Tilray is a leading cannabis producer, with more than 6 million square feet of cultivation capacity across Canada, Portugal and Germany, and a leading low-cost production base in the world’s largest legally regulated markets, supported by one of the largest EU-GMP certified footprints in the world. In beer, the world’s largest consumed alcoholic beverage category, we are the #4 craft brewer in the U.S. and #1 in the U.K., and we are very proud that Carlsberg has partnered with Tilray to begin producing and selling its iconic brands in the U.S. market starting January 1, 2027. Across beverage and wellness, we are accelerating innovation and staying closer to consumers. These leadership positions reflect the work we have done to integrate our businesses, sharpen operations and build a more focused, profitable company. Tilray is building a category-defining global platform for the next generation of wellness, healthcare and consumer products, with the brands, infrastructure and scale to lead as these markets evolve.”

The quarter’s performance reflects Tilray’s focus on building durable growth across multiple categories, strengthening profitability and maintaining a disciplined balance sheet while investing behind the long-term opportunities we believe will define the future of cannabis, beverage, wellness and healthcare.

Financial Highlights
All comparisons made to the prior year period

• Net revenue increased 23% year-over-year to $257.1 million in the first quarter, compared to $209.5 million.
• Gross profit increased 35% year-over-year to $77.5 million in the first quarter, compared to $57.5 million, while gross margin expanded to 30% from 27%.
• Cannabis net revenue was $56.1 million in the first quarter compared to $64.5 million.
  • Cannabis gross profit was $22.0 million in the first quarter compared to $23.3 million.
  • Cannabis gross margin expanded to 39% in the first quarter compared to 36%.
• Beverage net revenue increased 82% year-over-year to $101.5 million in the first quarter, compared to $55.7 million, reflecting the acquisition of BrewDog.
  • Beverage gross profit increased to $42.0 million in the first quarter compared to $21.3 million.
  • Beverage gross margin expanded to 41% in the first quarter compared to 38%.
• Distribution net revenue increased 14% to $84.3 million in the first quarter compared to $74.0 million.
  • Distribution gross profit increased $9.1 million in the first quarter compared to $8.0 million.
  • Distribution gross margin was 11% in the first quarter and was unchanged.
• Wellness net revenue was $15.3 million, consistent with the previous year period.
  • Wellness gross profit was $4.4 million in the first quarter compared to $4.9 million.
  • Wellness gross margin was 29% in the first quarter compared to 32%.
• Driven predominantly by non-cash charges, net loss was $40.0 million in the first quarter and net loss per share was $0.32. Adjusted net loss²  was $3.0 million in the first quarter and adjusted net loss per share or adjusted EPS² was $0.02.
• Adjusted EBITDA³ was $9.2 million in the first quarter compared to $10.2 million; burdened by approximately $1.7 million of global fuel surcharges in this quarter.

Balance Sheet Update: Tilray’s balance sheet remains strong, supported by cash, restricted cash and marketable securities⁴ of $221.4 million at the end of the first quarter. This position gives the Company financial flexibility to invest behind strategic growth opportunities, support integration priorities and maintain disciplined capital allocation. Fiscal year to date, Tilray also reduced total outstanding debt by $42 million.

Fiscal Year 2027 Guidance
For its fiscal year ending May 31, 2027, the Company reaffirms its expectation to achieve adjusted EBITDA³ of $68 million to $75 million, representing double-digit growth as compared to fiscal year 2026. Historically, due to the seasonality of our business, financial results are typically more weighted toward the second half of the fiscal year, with results strengthening significantly in the fourth quarter.

Management’s guidance for adjusted EBITDA³ is provided on a non-GAAP basis and excludes stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; impairments of intangible assets and goodwill; other than temporary change in fair value of convertible notes receivable; litigation costs; integration and restructuring costs; transaction-related costs; and other non-operating income (expenses) and non-recurring items that may be incurred during the Company’s fiscal year 2027, which the Company will continue to identify as it reports its future financial results.

The Company cannot reconcile its expected adjusted EBITDA³ to net income under “Fiscal Year 2027 Guidance” without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time.

____________________________________________________________________________________________________

^{(1) Net (debt) cash is a non-GAAP financial measure. See “Use of Non-GAAP Measures” below for additional discussion regarding these non-GAAP measures and for a reconciliation of such Non-GAAP Measures to our most comparable GAAP measure.
(2) Adjusted net income (loss) and adjusted net income (loss) per share/Adjusted EPS are a non-GAAP financial measure. See “Use of Non-GAAP Measures” below for additional discussion regarding these non-GAAP measures and for a reconciliation of such Non-GAAP Measures to our most comparable GAAP measure.
(3) Adjusted EBITDA is a non-GAAP financial measure. See “Use of Non-GAAP Measures” below for additional discussion regarding these non-GAAP measures and for a reconciliation of such Non-GAAP Measures to our most comparable GAAP measure.
(4) Cash, restricted cash and Marketable Securities is a non-GAAP financial measure. See “Use of Non-GAAP Measures” below for additional discussion regarding these non-GAAP measures and for a reconciliation of such Non-GAAP Measures to our most comparable GAAP measure.}

Live Audio Webcast
Tilray Brands will host a webcast to discuss these results today at 8:30 AM Eastern Time. Investors may access the live webcast through the Events and Presentations section of Tilray’s Investor Relations website, where a replay will also be available and archived.

About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Cautionary Statement Concerning Forward-Looking Statements
Certain statements in this press release constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “position,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.

Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become a leading lifestyle consumer packaged goods company; the Company’s ability to become a leading beverage alcohol Company; the Company’s ability to achieve long term profitability; the Company’s ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company’s ability to successfully achieve revenue growth, margin and profitability improvements, production and supply chain efficiencies, synergies and cost savings; the Company’s ability to achieve fiscal year 2027 financial guidance, including expected Adjusted EBITDA³ of $68 to $75 million and synergy optimizations; the Company’s expected revenue growth, sales volume, profitability, synergies and accretion related to any of its acquisitions; expected opportunities in the U.S., including upon U.S. federal cannabis legalization or rescheduling and the Company’s ability to leverage its platform in connection therewith; the Company’s ability to successfully leverage artificial intelligence strategies; the Company’s anticipated investments and acquisitions, including in organic and strategic growth, partnership efforts, product offerings and other initiatives; and the Company’s ability to commercialize new and innovative products.

Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Use of Non-U.S. GAAP Financial Measures
This press release and the accompanying tables include non-GAAP financial measures, including Adjusted EBITDA³, Adjusted cash operating income (loss), Adjusted net income (loss), Adjusted net income (loss) per share and or (“Adjusted EPS”), free cash flow, adjusted free cash flow, constant currency presentations of revenue, cash, restricted cash and marketable securities, and net (debt) cash. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company’s operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures, nor should adjusted net income (loss) per share be used as a measure of liquidity. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company’s Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.

Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, impairments of intangible assets and goodwill, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company’s GAAP financial results.

The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company’s consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year. A reconciliation of prior year revenue to constant currency revenue, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

Adjusted EBITDA³ is calculated as net income (loss) before income tax expense (recovery), net; interest expense, net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; project 420 optimization costs; litigation costs; restructuring costs, and transaction costs, net. A reconciliation of Adjusted EBITDA³ to net income (loss), the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.

Adjusted cash operating income (loss) is calculated as operating loss, less; amortization; stock-based compensation; and change in fair value of contingent consideration. A reconciliation of adjusted cash operating income (loss) to operating loss, the most directly comparable GAAP measure, has been included below in this press release. Adjusted cash operating income (loss) is not calculated in accordance with GAAP and should not be considered an alternative for GAAP operating income or as a measure of liquidity.

Adjusted net income (loss) is calculated as net loss attributable to stockholders of Tilray Brands, Inc., less; non-operating income (expense), net; amortization; deferred income tax expense (benefits), net; stock-based compensation; Accretion of convertible debt discount; change in fair value of contingent consideration; project 420 optimization costs; litigation costs; restructuring costs and transaction costs, net. A reconciliation of Adjusted net income (loss) to net loss attributable to stockholders of Tilray Brands, Inc., the most directly comparable GAAP measure, has been included below in this press release.

Adjusted net income (loss) per share (and or adjusted EPS) is calculated as adjusted net income (loss) divided by weighted average number of common shares outstanding. A reconciliation of Adjusted net income (loss) per share to net loss attributable to stockholders of Tilray Brands, Inc., the most directly comparable GAAP measure, has been included below in this press release. Adjusted net income (loss) per share is not calculated in accordance with GAAP and should not be considered an alternative for GAAP net income (loss) per share or as a measure of liquidity.

Free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release. Adjusted free cash flow is comprised of two GAAP measures which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets, net, and the exclusion of growth CAPEX from investments in capital and intangible assets, net, which excludes the amount of capital expenditures that are considered to be associated with growth of future operations rather than to maintain the existing operations of the Company, and excludes cash paid for litigation settlements. A reconciliation of net cash flow provided by (used in) operating activities to adjusted free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included above in this press release.

Cash, restricted cash and marketable securities are comprised of three GAAP measures, cash and cash equivalents and restricted cash added to marketable securities. The Company’s management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combining these three GAAP metrics.

Net (debt) cash is comprised of GAAP measures and reduces bank indebtedness, current and non-current portions of long-term debt, the principal balance of convertible debt by cash and cash equivalents and marketable securities. The Company believes this metric provides useful information to management, analysts, and investors regarding its liquidity and the Company’s ability to repay all of its debt.

Contacts:
Investor Relations
investors@tilray.com
Pro-TLRY@prosek.com

Media
news@tilray.com

The accompanying excerpts of the interim condensed consolidated financial statements are unaudited and have been prepared in accordance with U.S. GAAP. 

Consolidated Statements of Financial Position
	August 31,				May 31,
(in thousands of US dollars)	2026				2026
Assets
Current assets
Cash and cash equivalents	$	214,960			$	225,977
Restricted cash		3,383				3,365
Marketable securities		3,047				5,289
Accounts receivable, net		190,617				189,170
Inventory		328,973				301,192
Prepaids and other current assets		64,160				64,692
Assets held for sale		2,449				2,449
Total current assets		807,589				792,134
Capital assets		665,923				680,225
Operating lease, right-of-use assets		42,030				42,318
Digital assets		720				674
Intangible assets		42,468				42,779
Goodwill		752,350				752,350
Long-term investments		6,365				6,551
Other assets		10,509				10,981
Total assets	$	2,327,954			$	2,328,012
Liabilities
Current liabilities
Bank indebtedness	$	8,688			$	8,775
Accounts payable and accrued liabilities		335,415				318,088
Current portion of lease liabilities		11,902				13,357
Current portion of long-term debt		15,457				18,160
Current portion of convertible debentures payable		59,224				—
Total current liabilities		430,686				358,380
Long – term liabilities
Lease liabilities		158,610				158,155
Long-term debt		118,046				120,425
Convertible debentures payable		—				79,529
Deferred tax liabilities, net		9,746				12,256
Other liabilities		4,192				4,400
Total liabilities		721,280				733,145
Stockholders’ equity
Common stock ($0.0001 par value; 1,416,000,000 common shares authorized; 144,936,074 and 131,683,075 common shares issued and outstanding, respectively)		145				132
Treasury Stock (1,124,869 and 589,217 treasury shares issued and outstanding, respectively)		—				—
Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively)		—				—
Additional paid-in capital		6,674,469				6,627,056
Accumulated other comprehensive loss		(39,492	)			(44,233	)
Accumulated deficit		(5,011,764	)			(4,968,623	)
Total Tilray Brands, Inc. stockholders’ equity		1,623,358				1,614,332
Non-controlling interests		(16,684	)			(19,465	)
Total stockholders’ equity		1,606,674				1,594,867
Total liabilities and stockholders’ equity	$	2,327,954			$	2,328,012

Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
	For the three months ended
	August 31,				August 31,				Change				% Change
(in thousands of U.S. dollars, except for per share data)	2026				2025				2026 vs. 2025
Net revenue	$	257,147			$	209,501			$	47,646			23	%
Cost of goods sold		179,638				152,032				27,606			18	%
Gross profit		77,509				57,469				20,040			35	%
Operating expenses:
General and administrative		57,608				41,053				16,555			40	%
Selling		13,593				12,923				670			5	%
Amortization		6,500				3,929				2,571			65	%
Marketing and promotion		15,736				10,155				5,581			55	%
Research and development		89				41				48			117	%
Change in fair value of contingent consideration		—				(15,000	)			15,000			(100	)%
Litigation costs, net of recoveries		787				1,007				(220	)		(22	)%
Restructuring costs		2,447				869				1,578			182	%
Transaction costs, net		4,802				400				4,402			1101	%
Total operating expenses		101,562				55,377				46,185			83	%
Operating income (loss)		(24,053	)			2,092				(26,145	)		(1250	)%
Interest expense, net		(6,480	)			(6,696	)			216			(3	)%
Non-operating income (expense), net		(7,773	)			3,832				(11,605	)		(303	)%
(Loss) before income taxes		(38,306	)			(772	)			(37,534	)		4862	%
Income tax expense (recovery), net		1,725				(2,285	)			4,010			(175	)%
Net income (loss)	$	(40,031	)		$	1,513			$	(41,544	)		(2746	)%
Total net income (loss) attributable to:
Stockholders of Tilray Brands, Inc.		(43,141	)			(322	)			(42,819	)		13298	%
Non-controlling interests		3,110				1,835				1,275			69	%
Other comprehensive gain (loss), net of tax
Foreign currency translation gain (loss)		4,412				(188	)			4,600			(2447	)%
Comprehensive income (loss)	$	(35,619	)		$	1,325			$	(36,944	)		(2788	)%
Total comprehensive income (loss) attributable to:
Stockholders of Tilray Brands, Inc.		(38,400	)			(489	)			(37,911	)		7753	%
Non-controlling interests		2,781				1,814				967			53	%
Weighted average number of common shares – basic1		133,340,533				106,027,190				27,313,343			26	%
Weighted average number of common shares – diluted1		133,340,533				106,027,190				27,313,343			26	%
Net loss per share – basic1	$	(0.32	)		$	(0.00	)		$	(0.32	)		10553	%
Net loss per share – diluted1	$	(0.32	)		$	(0.00	)		$	(0.32	)		10553	%
1The prior year share and amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on December 2, 2025. See Note 1 (Basis of presentation and summary of significant accounting policies) within the Form 10-Q for the period ended August 31, 2026.

Condensed Consolidated Statements of Cash Flows
	For the three months ended
	August 31,				August 31,				Change				% Change
(in thousands of US dollars)	2026				2025				2026 vs. 2025
Cash provided by (used in) operating activities:
Net income (loss)	$	(40,031	)		$	1,513			$	(41,544	)		(2746	)%
Adjustments for:
Income tax expense (recovery), net		1,725				(2,285	)			4,010			(175	)%
Unrealized foreign exchange (gain) loss		4,524				(2,328	)			6,852			(294	)%
Amortization		18,638				15,561				3,077			20	%
Accretion of convertible debt discount		1,465				1,976				(511	)		(26	)%
Unrealized (gain) loss on digital assets		(46	)			8				(54	)		(675	)%
Other non-cash items		(1,745	)			282				(2,027	)		(719	)%
Stock-based compensation		6,584				5,052				1,532			30	%
Loss (gain) on long-term investments		27				(39	)			66			(169	)%
Loss on derivative instruments		—				3,670				(3,670	)		(100	)%
Change in fair value of contingent consideration		—				(15,000	)			15,000			(100	)%
Change in non-cash working capital:
Accounts receivable		(1,319	)			14,414				(15,733	)		(109	)%
Prepaids and other current assets		1,004				(7,133	)			8,137			(114	)%
Inventory		(27,781	)			(11,905	)			(15,876	)		133	%
Accounts payable and accrued liabilities		20,414				(5,127	)			25,541			(498	)%
Net cash used in operating activities		(16,541	)			(1,341	)			(15,200	)		1133	%
Cash provided by (used in) investing activities:
Investment in capital and intangible assets		(11,009	)			(9,523	)			(1,486	)		16	%
Proceeds from disposal of capital and intangible assets		101				293				(192	)		(66	)%
Investment in digital assets		—				(1,000	)			1,000			(100	)%
Sale (purchase) of marketable securities, net		2,242				34,697				(32,455	)		(94	)%
Proceeds from long-term investments		133				—				133			NM
Business acquisitions, net of cash acquired		(720	)			—				(720	)		NM
Net cash used in investing activities		(9,253	)			24,467				(33,720	)		(138	)%
Cash provided by (used in) financing activities:
Share capital issued, net of cash issuance costs		22,338				22,491				(153	)		(1	)%
Repayment of long-term debt		(5,846	)			(2,653	)			(3,193	)		120	%
Repayment of lease liabilities		(2,438	)			(994	)			(1,444	)		145	%
Net (increase) decrease in bank indebtedness		(87	)			1,004				(1,091	)		(109	)%
Net cash provided by financing activities		13,967				19,848				(5,881	)		(30	)%
Effect of foreign exchange on cash and cash equivalents		828				188				640			340	%
Net increase (decrease) in cash and cash equivalents		(10,999	)			43,162				(54,161	)		(125	)%
Cash and cash equivalents, beginning of period		229,342				221,666				7,676			3	%
Cash and cash equivalents and restricted cash, end of period	$	218,343			$	264,828			$	(46,485	)		(18	)%

Net Revenue by Operating Segment
	For the three months ended						For the three months ended
(In thousands of U.S. dollars)	August 31, 2026				% of Total Revenue		August 31, 2025				% of Total Revenue
Beverage business	$	101,496			39%		$	55,739			27%
Cannabis business		56,109			22%			64,511			31%
Distribution business		84,266			33%			74,007			35%
Wellness business		15,276			6%			15,244			7%
Total net revenue	$	257,147			100%		$	209,501			100%
Net Revenue by Operating Segment in Constant Currency
	For the three months ended						For the three months ended
	August 31, 2026						August 31, 2025
(In thousands of U.S. dollars)	as reported in constant currency				% of Total Revenue		as reported in constant currency				% of Total Revenue
Beverage business	$	101,777			39%		$	55,739			27%
Cannabis business		56,873			22%			64,511			31%
Distribution business		85,188			33%			74,007			35%
Wellness business		15,433			6%			15,244			7%
Total net revenue	$	259,271			100%		$	209,501			100%
Net Cannabis Revenue by Market Channel
	For the three months ended						For the three months ended
(In thousands of U.S. dollars)	August 31, 2026				% of Total Revenue		August 31, 2025				% of Total Revenue
Revenue from Canadian medical cannabis	$	4,717			8%		$	6,146			10%
Revenue from Canadian adult-use cannabis		53,564			95%			64,067			99%
Revenue from wholesale cannabis		673			1%			4,155			6%
Revenue from international cannabis		16,237			29%			13,367			21%
Less excise taxes		(19,082	)		(33)%			(23,224	)		(36)%
Total	$	56,109			100%		$	64,511			100%
Net Cannabis Revenue by Market Channel in Constant Currency
	For the three months ended						For the three months ended
	August 31, 2026						August 31, 2025
(In thousands of U.S. dollars)	as reported in constant currency				% of Total Revenue		as reported in constant currency				% of Total Revenue
Revenue from Canadian medical cannabis	$	4,804			8%		$	6,146			10%
Revenue from Canadian adult-use cannabis		54,575			96%			64,067			99%
Revenue from wholesale cannabis		685			1%			4,155			6%
Revenue from international cannabis		16,252			29%			13,367			21%
Less excise taxes		(19,443	)		(34)%			(23,224	)		(36)%
Total	$	56,873			100%		$	64,511			100%

Other Financial Information: Key Operating Metrics
	For the three months ended
	August 31,				August 31,
(in thousands of U.S. dollars)	2026				2025
Net beverage revenue	$	101,496			$	55,739
Net cannabis revenue		56,109				64,511
Distribution revenue		84,266				74,007
Wellness revenue		15,276				15,244
Beverage costs		59,489				34,413
Cannabis costs		34,087				41,241
Distribution costs		75,143				66,008
Wellness costs		10,919				10,370
Gross profit		77,509				57,469
Beverage gross margin		41	%			38	%
Cannabis gross margin		39	%			36	%
Distribution gross margin		11	%			11	%
Wellness gross margin		29	%			32	%
Adjusted EBITDA	$	9,205			$	10,181
Cash and cash equivalents, restricted cash and marketable securities as at the period ended:		221,390				264,828
Working capital as at the period ended:	$	376,903			$	433,508

Other Financial Information: Gross Margin and Adjusted Gross Margin
	For the three months ended August 31, 2026
(In thousands of U.S. dollars)	Beverage				Cannabis				Distribution				Wellness				Total
Net revenue	$	101,496			$	56,109			$	84,266			$	15,276			$	257,147
Cost of goods sold		59,489				34,087				75,143				10,919				179,638
Gross profit		42,007				22,022				9,123				4,357				77,509
Gross margin		41	%			39	%			11	%			29	%			30	%
	For the three months ended August 31, 2025
(In thousands of U.S. dollars)	Beverage				Cannabis				Distribution				Wellness				Total
Net revenue	$	55,739			$	64,511			$	74,007			$	15,244			$	209,501
Cost of goods sold		34,413				41,241				66,008				10,370				152,032
Gross profit		21,326				23,270				7,999				4,874				57,469
Gross margin		38	%			36	%			11	%			32	%			27	%

Other Financial Information: Adjusted Earnings Before Interest, Taxes and Amortization
	For the three months ended
	August 31,				August 31,				Change				% Change
(In thousands of U.S. dollars)	2026				2025				2026 vs. 2025
Net income (loss)	$	(40,031	)		$	1,513			$	(41,544	)		(2746	)%
Income tax expense (recovery), net		1,725				(2,285	)			4,010			(175	)%
Interest expense, net		6,480				6,696				(216	)		(3	)%
Non-operating expense (income), net		7,773				(3,832	)			11,605			(303	)%
Amortization		18,638				15,561				3,077			20	%
Stock-based compensation		6,584				5,052				1,532			30	%
Change in fair value of contingent consideration		—				(15,000	)			15,000			(100	)%
Project 420 business optimization		—				200				(200	)		(100	)%
Litigation costs, net of recoveries		787				1,007				(220	)		(22	)%
Restructuring costs		2,447				869				1,578			182	%
Transaction costs, net		4,802				400				4,402			1101	%
Adjusted EBITDA	$	9,205			$	10,181			$	(976	)		(10	)%
Other Financial Information: Adjusted cash operating income (loss)
	For the three months ended
	August 31,				August 31,				Change				% Change
	2026				2025				2026 vs. 2025
Operating income (loss)	$	(24,053	)		$	2,092			$	(26,145	)		(1250	)%
Change in fair value of contingent consideration		—				(15,000	)			15,000			(100	)%
Amortization		18,638				15,561				3,077			20	%
Stock-based compensation		6,584				5,052				1,532			30	%
Adjusted cash operating income (loss)	$	1,169			$	7,705			$	(6,536	)		(85	)%
Other Financial Information: Adjusted net income (loss) and Adjusted net income (loss) per share (“Adjusted EPS”)
	August 31,				August 31,				Change				% Change
	2026				2025				Change
Net loss attributable to stockholders of Tilray Brands, Inc.	$	(43,141	)		$	(322	)		$	(42,819	)		13298	%
Non-operating expense (income), net		7,773				(3,832	)			11,605			(303	)%
Amortization		18,638				15,561				3,077			20	%
Stock-based compensation		6,584				5,052				1,532			30	%
Deferred income tax expense (benefits), net		(2,344	)			(2,537	)			193			(8	)%
Accretion of convertible debt discount		1,465				1,976				(511	)		(26	)%
Change in fair value of contingent consideration		—				(15,000	)			15,000			(100	)%
Project 420 business optimization		—				200				(200	)		(100	)%
Litigation costs, net of recoveries		787				1,007				(220	)		(22	)%
Restructuring costs		2,447				869				1,578			182	%
Transaction costs, net		4,802				400				4,402			1101	%
Adjusted net income (loss)	$	(2,989	)		$	3,374			$	(6,363	)		(189	)%
Adjusted net income (loss) per share – basic and diluted	$	(0.02	)		$	0.03			$	(0.05	)		(167	)%
Other Financial Information: Free Cash Flow
	For the three months ended
	August 31,				August 31,				Change				% Change
(In thousands of U.S. dollars)	2026				2025				2026 vs. 2025
Net cash used in operating activities	$	(16,541	)		$	(1,341	)		$	(15,200	)		1133	%
Less: investments in capital and intangible assets, net		(10,908	)			(9,230	)			(1,678	)		18	%
Free cash flow	$	(27,449	)		$	(10,571	)		$	(16,878	)		160	%
Add: growth CAPEX		3,025				3,009				16			1	%
Add: cash paid for litigation settlements		1,000				2,804				(1,804	)		(64	)%
Adjusted free cash flow	$	(23,424	)		$	(4,758	)		$	(18,666	)		392	%

The new generation of Pulsar Max introduces ISO 15118-ready hardware designed to support evolving European AFIR charging requirements, alongside built-in RFID and Ethernet connectivity

BARCELONA, Spain, Oct. 08, 2026 (GLOBE NEWSWIRE) — Wallbox (NYSE: WBX), a global leader in electric vehicle (EV) charging and energy management solutions, today announced the European launch of the new generation of Pulsar Max, its compact AC charging solution for homes and shared residential environments.

Building on the success of the Pulsar platform, with more than 600,000 Wallbox chargers sold worldwide, the new Pulsar Max introduces enhanced connectivity, access control and future-ready hardware designed to make EV charging easier to install, connect and manage across a broader range of residential applications.

The new Pulsar Max incorporates ISO 15118-ready hardware, including an integrated Power Line Communication (PLC) hardware layer that provides the foundation for future vehicle-to-charger communication and smart charging capabilities. This architecture is designed to support AFIR-related use cases where applicable and help customers and installers prepare for evolving European charging requirements.

The new model also introduces built-in RFID authentication and Ethernet connectivity, complementing the existing Bluetooth and Wi-Fi options. Ethernet enables installers to connect multiple chargers through the same local network, while RFID authentication provides a simple way to identify and manage different users. Together, these capabilities make Pulsar Max particularly suited to shared residential environments such as condominiums and multi-tenant buildings.

“As electric mobility becomes mainstream, residential charging needs to evolve beyond simply delivering power to a vehicle,” said Eduard Castañeda, Chief Product and Technology Officer at Wallbox. “With the new Pulsar Max, we are combining the simplicity and compact design that have defined the Pulsar family with greater connectivity, user identification and hardware designed for the next generation of EV charging.”

Pulsar Max is available in three configurations: tethered versions offering 7.4 kW or 22 kW of charging power, and a 22 kW socket version. All variants can be managed through the Wallbox App and support Bluetooth, Wi-Fi and Ethernet connectivity, giving installers and drivers greater flexibility across different installation environments.

The new generation also retains Wallbox’s intelligent energy management capabilities, including the ability to charge using surplus solar energy. Pulsar Max is backed by a five-year product warranty, subject to the terms and conditions of sale, reinforcing Wallbox’s focus on reliability and long-term residential charging.

The new Pulsar Max is expected to be available across European markets from November 2026, with rollout beginning progressively across the region.

About Wallbox

Wallbox is a global technology company, dedicated to changing the way the world uses energy. Wallbox creates advanced electric vehicle charging and energy management systems that redefine the relationship between users and the network. Wallbox goes beyond charging electric vehicles to give users the power to control their consumption, save money and live more sustainably. Wallbox offers a complete portfolio of charging and energy management solutions for residential, semi-public, and public use in more than 100 countries around the world. Founded in 2015 in Barcelona, where the company’s headquarters are located, Wallbox currently has offices across Europe, Asia, and America. For more information, visit www.wallbox.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Wallbox intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements regarding Wallbox’s expected future operating results and financial position, growth, profitability and cost optimization, including the expected impact of Wallbox’s renewed capital structure; industry and company growth, and Wallbox’s business strategy and plans and related reinforcement of Wallbox’s sales and service organization. The words “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “focus,” “forecast,” “intend,” “likely,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: Wallbox’s history of operating losses; risks related to the restructuring plan, including Wallbox’s inability to achieve projected operating improvements following the restructuring; the adoption and demand for electric vehicles including the success of alternative fuels, changes to rebates, tax credits and the impact of government incentives or reduction thereof; political and economic uncertainty and macroeconomic factors, such as impacts from tariffs and trade barriers, geopolitical conflicts, consumer spending, inflation and foreign exchange rates; the accuracy of Wallbox’s forecasts and projections including those regarding its market opportunity; competition; risks related to losses or disruptions in Wallbox’s supply or manufacturing partners; Wallbox’s reliance on the third-parties outside of its control; risks related to Wallbox’s technology, intellectual property and infrastructure; executive orders and regulatory changes under the U.S. political administration and uncertainty therefrom, as well as the other important factors discussed under the caption “Risk Factors” in Wallbox’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, as such factors may be updated from time to time in its other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of Wallbox’s website at investors.wallbox.com. Any such forward-looking statements represent management’s estimates as of the date of this press release. Any forward-looking statement that Wallbox makes in this press release speaks only as of the date of such statement. Except as required by law, Wallbox disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Wallbox Public Relations Contact:
Albert Cabanes
Public Relations
Press@wallbox.com